Lupin
Lupin delivered a strong Q3 FY26 with revenue of ₹7,168 crore (+24% YoY) and EBITDA margin of 31.1% (+681 bps YoY), driven by broad-based growth across regions.
Lupin vs Biocon Q3 FY26
Side-by-side earnings comparison across verified financials, sentiment, risks, and management commentary.
Biocon
Biocon delivered a solid Q3 FY26 with group revenue of ₹4,173 crore (+9% YoY) and EBITDA of ₹951 crore (+21% YoY), driven by strong biosimilar margins (28% vs 21% last year) and generics growth of 24%.
Result Snapshot
Revenue₹7,168 Cr₹4,173 Cr
PAT₹1,181 Cr₹-52 Cr
EBITDA Margin31.1%20%
Sentimentbullishbullish
Key Quotes
We are pleased to report another quarter of strong execution with revenues surpassing last quarter's record performance. This marks our 14th consecutive quarter of year-on-year growth.
Q3 FY26 represents an important operational inflection point for Biocon. With major capex now largely behind us and operating leverage beginning to play out, we are progressing from a phase of balance sheet resilience into a cycle of sustainable growth, margin expansion and a cash flow-led value creation.